$BCLI $10 valuation as NurOwn™ Phase 2 Clinical Trial Data to be Reported in Mid 2016 http://s1.q4cdn.com/460208960/files/News/2016/May-17-2016_BCLI_Bautz.pdf?utm_content=bufferbd490&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer $BCLI A key P2 trial of NurOwn in Amyotrophic Lateral Sclerosis (ALS) will be complete by the end of April. Results expected by mid-year.